Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07085728 · ClinicalTrials.gov registry record · Phase 2
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Active
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT07085728 is a Phase 2 study that is active but no longer recruiting, run by Eastern Cooperative Oncology Group. The registered enrollment target is 74 participants.
The verdict
NCT07085728, a Phase 2 study, is active but no longer recruiting, sponsored by Eastern Cooperative Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with multiple myeloma and have kidney failure? This study is being done because the investigators want to find out if this approach is better or worse than the usual approach for the participant's newly diagnosed multiple myeloma. The usual approach is defined as care most people get for multiple myeloma. If the participant decides to take part in this study, they will either get the study medications daratumumab-hyaluronidase, bortezomib, and dexamethasone for four months (4 cycles), or the typical medications used to treat your cancer (cyclophosphamide, bortezomib, and dexamethasone) for 4 months (4 cycles). After the participant finishes their study treatment, their doctor will continue to follow their condition for 10 years to watch them for side effects and monitor their disease status. Their doctor will follow up with them every 3 months for years 1 and 2 and then every 6 months for years 3 through 10.
Interventions
- DRUG Cyclophosphamide
- DRUG Dexamethasone
- DRUG Bortezomib (VELCADE)
- DRUG Daratumumab-hyaluronidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07085728
The ClinicalTrials.gov registry entry for NCT07085728 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07085728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07085728 about?
NCT07085728 is a clinical study titled "Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure". This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with multiple myeloma and have kidney failure? This study is being done because...
What is the current status of trial NCT07085728?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2025-08-11. Estimated completion is 2027-02-01.
What interventions are being tested in trial NCT07085728?
The interventions under investigation include: Cyclophosphamide (DRUG), Dexamethasone (DRUG), Bortezomib (VELCADE) (DRUG), Daratumumab-hyaluronidase (DRUG).
Who is sponsoring clinical trial NCT07085728?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.